FcRL5/Luciferase RPMI-8226 Cell Line

Description

FcRL5/Luciferase RPMI-8226 Cell Line is a genetically engineered human multiple myeloma model featuring stable overexpression of Fc receptor-like 5 (FcRL5) combined with luciferase reporter integration. This dual-modified cell line maintains characteristic plasma cell morphology and retains native multiple myeloma markers (CD38, CD138) while enabling sensitive bioluminescent tracking of tumor progression. The constitutive FcRL5 expression creates a physiologically relevant model for studying FcRL5-mediated signaling pathways and evaluating targeted therapies against this emerging multiple myeloma antigen. The luciferase reporter permits quantitative monitoring of tumor growth kinetics and drug response through non-invasive bioluminescence imaging, providing a powerful tool for investigating FcRL5 function in tumor survival and drug resistance mechanisms. Cryopreserved at low passage (<P20) to ensure genetic stability and consistent reporter expression. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast and Bacteria.